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Cancer is the leading cause of disease-related death in teenagers and young adults aged 13–24 years (TYAs) in England. We have
analysed national 5-year relative survival among more than 30000 incident cancer cases in TYAs. For cancer overall, 5-year survival
improved from 63% in 1979–84 to 74% during 1996–2001 (Po0.001). However, there were no sustained improvements in survival
over time among high-grade brain tumours and bone and soft tissue sarcomas. Survival patterns varied by age group (13–16, 17–20,
21–24 years), sex and diagnosis. Survival from leukaemia and brain tumours was better in the youngest age group but in the oldest
from germ-cell tumours (GCTs). For lymphomas, bone and soft tissue sarcomas, melanoma and carcinomas, survival was not
significantly associated with age. Females had a better survival than males except for GCTs. Most groups showed no association
between survival and socioeconomic deprivation, but for leukaemias, head and neck carcinoma and colorectal carcinoma, survival was
significantly poorer with increasing deprivation. These results will aid the development of national specialised service provision for this
age group and identify areas of clinical need that present the greatest challenges.
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In 2004 in England, over 50% of cancers were diagnosed at age 70
years and above, with only 0.5% in 15–24-year-olds (Office for
National Statistics, 2006). However, cancer is the leading disease-
related cause of death in this age range (Geraci et al, 2007). There
is growing recognition that young cancer patients have special
physical, social and educational needs in addition to appropriate
disease-specific treatment. Risks of developing treatment-induced
second malignancies and organ dysfunction are critical considera-
tions in the young. Loss of fertility and other organ-specific
cytotoxic effects and disruption to education, vocational and
professional training can have a profound influence on future life
(National Collaborating Centre for Cancer, 2005).
Detailed national survival data for this age group have not been
reported hitherto but are important for service planning and as a
baseline for monitoring progress. We now describe survival trends
over time and patterns of survival by age, sex and socioeconomic
deprivation for a 23-year series of 13- to 24-year-olds with cancer
in England.
MATERIALS AND METHODS
Teenagers and young adults aged 13–24 years (TYAs) diagnosed
with malignancy in England, during the period 1979–2001,
followed up to 31 December 2003, were included in this study.
National cancer registration data on individual eligible cases were
supplied by the National Cancer Intelligence Centre, Office for
National Statistics, London (ONS), including dates of birth,
diagnosis and follow-up, sex, histological type and primary site
of cancer, Townsend deprivation index score (TDI) and vital
status. Cases with vital status unknown (patient record not traced
at the National Health Service Central Register) were excluded as
were cases with a survival time of zero (diagnosed and died on the
same day). These exclusion criteria were those applied by Coleman
et al (1999). Cases lost to follow-up, for example, emigrated, were
included up to date last known to be alive.
For cases registered from 1979 to 1994, cancer morphology was
coded according to the International Classification of Diseases for
Oncology, first edition (ICD-O 1) (World Health Organization,
1976), and cancer site according to the ninth revision of the
International Classification of Diseases (ICD 9) (World Health
Organization, 1977). For cases registered during the period 1995–
2001, diagnoses were similarly coded according to ICD-O, second
edition (ICD-O 2) (Percy et al, 1990), and ICD tenth revision (ICD-
10) (World Health Organization, 1992). The cases were classified
into 10 main diagnostic groups and 2–7 subgroups per main
group as described previously (Birch et al, 2002). This classifica-
tion is recognised internationally as a suitable vehicle for analysing
data on TYAs (Barr et al, 2006).
We examined survival for each diagnostic subgroup by age at
diagnosis (13–16, 17–20, 21–24 years), TDI, sex and calendar
period (1979–1984, 1985–1989, 1990–1995, 1996–2001). Cases
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deprived, on the basis of the quintile of the distribution of TDIs for
census ward of residence. TDIs are derived from levels of four
census variables: car ownership; house ownership; overcrowding
and unemployment within wards, giving a measure of material
deprivation (Townsend et al, 1998).
Five-year relative survival in each diagnostic group was
calculated by dividing observed by expected survival among
comparable groups in the general population (Ederer et al, 1961).
The 5-year expected survival was derived from the age, sex,
deprivation and calendar year-specific national mortality rates
for England (Coleman et al, 1999). Relative survival by age, sex,
calendar period and TDI was examined using Poisson regression
(Dickman et al, 2004, Breslow and Day, 1987). Specified diagnostic
subgroups with 250 (0.8%) or more cases as well as smaller groups
of interest were examined individually. The significance level was
set at 5%. Analyses were carried out using the statistical software
package Stata, Version 9 (StataCorp LP, 2005).
RESULTS
Survival time was available for 31876 (94.8%) of 33625 potentially
eligible patients. During the period from 1993 (when such
information became available) to 2001, 142 of 217 (65.4%) with
zero survival time were registered by death certificate only. The
remaining cases were hospital registrations who were diagnosed
and died on the same day.
Figure 1 shows that overall 5-year relative survival steadily
increased throughout the study period (Po0.001) from 63% in
1979–1984 to 77% in 1996–2001. The most marked increase was
between the two earliest periods.
Table 1 shows that 5-year relative survival was significantly
better for females than males except for germ cell tumours (GCTs)
and central nervous system (CNS) tumours. The pattern of survival
with age varied between diagnostic groups. For GCTs in 13- to
16-years-olds, 17- to 20-year-olds and 21- to 24-year-olds, survival
was 80, 87 and 90% respectively. However, for leukaemia and CNS
tumours, survival was better in the youngest group (Po0.001). For
lymphomas, bone sarcomas, soft tissue sarcomas (STSs), melano-
ma and carcinomas, survival was not significantly associated
with age. For leukaemia and carcinomas, the most deprived
groups had the lowest survival (P¼0.048 and 0.008, respectively).
All diagnostic groups showed improvements in 5-year relative
survival during the study period of between 9% (CNS) and 21%
(leukaemia), except STS for which no improvement was seen.
Tables 2–6 present the results of analyses by the major subtypes
within main diagnostic groups.
Table 2 shows 5-year survival of patients with haematological
malignancies. For acute lymphoid leukaemia (ALL), females had a
better survival than males (50 vs 43%, P¼0.019), survival
decreased with increasing age (Po0.001) and increased by 18%
during the study period from 37 to 55% (Po0.001). For acute
myeloid leukaemia (AML), there was an even greater improvement
over time, from 27 to 50% but from a lower starting point than
ALL. There were no significant differences in survival from AML
by age and sex. For chronic myeloid leukaemia, there was
a marked improvement in survival between the time periods
1979–1984 and 1985–1989 but no consistent further improve-
ment. Although there was a significant trend with TDI for
leukaemia overall (Table 1) there was no significant trend for
any subtype of leukaemia.
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Figure 1 Relative survival of cancer patients aged 13–24 years,
diagnosed between 1979 and 2001 in England, by calendar period.
Table 1 Five-year relative survival (%) of patients diagnosed at age 13–24 during 1979–2001 in England by main diagnostic group
All Leukaemia Lymphoma CNS Bone sarcomas STS GCTs Melanoma Carcinomas
N % PN % PN % PN % PN % PN % PN % PN % PN % P
Sex
Male 17339 69 o0.001 2129 42 0.016 4607 80 o0.001 1777 59 0.122 1170 46 0.019 950 52 0.012 4022 89 0.730 928 78 o0.001 1548 63 o0.001
Female 14433 73 1393 47 3583 84 1382 62 769 52 793 58 520 86 1768 89 3931 76
Age (years)
13–16 6682 65 o0.001 1303 47 o0.001 1644 82 0.772 1092 68 o0.001 815 48 0.611 495 58 0.455 381 80 o0.001 244 89 0.158 600 70 0.920
17–20 10107 70 1194 42 2948 81 922 61 716 46 611 51 1386 87 786 84 1363 73
21–24 14983 74 1025 40 3598 82 1145 53 408 54 637 55 2775 90 1666 85 3516 72
Deprivation
Most affluent 6353 71 0.001 700 45 0.048 1705 83 0.073 653 61 0.914 408 50 0.904 346 51 0.844 916 87 0.212 595 86 0.861 928 73 0.008
2 6353 71 725 46 1635 82 661 60 412 48 320 55 919 89 584 85 1011 73
3 6355 72 668 42 1663 82 648 62 366 47 339 60 914 89 571 85 1101 73
4 6355 71 723 43 1570 82 599 60 394 48 384 53 884 89 514 83 1168 73
Most deprived 6356 70 706 41 1617 80 598 60 359 51 354 53 909 89 432 87 1271 69
Year of diagnosis
1979–1984 7509 62 o0.001 935 33 o0.001 2031 77 o0.001 763 54 o0.001 544 39 o0.001 424 53 0.152 924 80 o0.001 454 74 o0.001 1309 64 o0.001
1985–1989 7482 71 789 43 2064 82 718 61 446 55 426 53 1063 85 606 86 1224 71
1990–1995 8488 73 929 47 2121 83 869 64 468 52 447 55 1220 92 850 86 1432 74
1996–2001 8293 77 869 54 1974 86 809 63 481 51 446 56 1335 94 786 90 1514 78
CNS¼central nervous system tumours; GCTs¼germ-cell tumours; STS¼soft tissue sarcoma.
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better survival than 17- to 24-year-olds (P¼0.033). There was a
marked improvement in survival between 1979–84 and 1985–89
but little subsequent improvement. For Hodgkin lymphoma (HL),
female patients had a small survival advantage over males
(P¼0.026), with significant improvements over time (Po0.001),
reaching 93% in the latest period. There was no significant trend in
survival with TDI for either NHL or HL.
Table 3 shows 5-year relative survival of patients with selected
CNS tumours. Only astrocytomas showed decreased survival with
increasing age (Po0.001), and this group showed no improvement
over the study period. This pattern was driven by high-grade
astrocytoma (HGA), which is more common in older age groups
(data not shown). For HGA, 5-year survival did not improve
during the study period (P¼0.85) and a very low survival rate of
14% was seen in the latest period. However, for low-grade
astrocytoma, 5-year survival improved from 76% in 1979–1984
to 90% in 1990–1995 but with no further improvement (P¼0.005).
The ‘other glioma’ group, mainly oligodendroglioma and epen-
dymoma, showed marked improvements from 1979 to 1995 but no
subsequent improvement. For medulloblastoma and supratentorial
primitive neuroectodermal tumours, there were no significant
Table 2 Five-year relative survival (%) of patients with haematological malignancies
a diagnosed at age 13–24 during 1979–2001 in England
ALL AML CML NHL HL
N % PN % PN % PN % PN % P
Sex
Male 1163 43 0.019 671 36 0.074 178 50 0.690 1552 65 0.206 3055 87 0.026
Female 633 50 565 42 116 54 789 68 2794 89
Age (years)
13–16 869 50 o0.001 333 40 0.536 54 43 0.372 599 70 0.033 1045 89 0.550
17–20 581 44 439 39 94 54 816 65 2132 88
21–24 346 37 464 38 146 54 926 66 2672 88
Deprivation
Most affluent 361 48 0.066 255 39 0.253 45 73 0.173 457 62 0.813 1248 90 0.190
2 400 48 240 43 53 43 452 69 1183 86
3 313 48 260 35 52 47 453 69 1210 86
4 371 43 252 41 62 51 457 66 1113 89
Most deprived 351 42 229 36 82 50 522 65 1095 87
Year of diagnosis
1979–1984 490 37 o0.001 311 27 o0.001 64 30 0.002 506 52 o0.001 1525 85 o0.001
1985–1989 416 45 259 34 71 62 569 70 1495 86
1990–1995 457 48 351 43 77 51 629 68 1492 89
1996–2001 433 55 315 50 82 66 637 72 1337 93
ALL¼acute lymphoid leukaemia; AML¼acute myeloid leukaemia; CML¼chronic myeloid leukaemia; HL¼Hodgkin lymphoma; NHL¼non-Hodgkin lymphoma.
aExcluding
196 cases with other rare and unspecified haematological malignancies.
Table 3 Five-year relative survival (%) of patients with selected CNS tumours diagnosed at age 13–24 during 1979–2001 in England
Astrocytoma Other glioma Ependymoma PNET Other specified and unspecified
N % PN % PN % PN % PN % P
Sex
Male 869 60 0.439 376 53 0.125 141 76 0.291 191 51 0.295 200 60 0.092
Female 749 59 251 61 110 84 117 57 155 69
Age (years)
13–16 574 71 o0.001 183 62 0.249 94 77 0.196 129 60 0.058 112 68 0.383
17–20 480 61 179 56 77 81 89 49 97 66
21–24 564 47 265 53 80 82 90 49 146 59
Deprivation
Most affluent 335 59 0.830 129 59 0.921 52 83 0.246 62 53 0.750 75 64 0.623
2 328 60 123 57 54 85 74 55 82 54
3 324 61 134 57 52 76 65 59 73 68
4 312 61 131 49 44 78 48 50 64 67
Most deprived 319 57 110 62 49 75 59 49 61 67
Year of diagnosis
1979–1984 359 56 0.199 184 49 0.002 64 71 0.014 78 50 0.118 78 49 0.006
1985–1989 347 62 153 55 62 74 66 46 90 69
1990–1995 443 60 159 64 61 89 77 59 129 65
1996–2001 469 59 131 61 64 85 87 61 58 74
PNET¼medulloblastoma and primitive neuroectodermal tumours.
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CNS tumour group showed a trend with TDI.
Table 4 shows 5-year relative survivals of patients with
bone tumours and STS. For osteosarcoma, females had a better
prognosis than males (P¼0.008) and survival improved signifi-
cantly between 1979–84 and 1985–89 but with no improvements
more recently. Thirteen- to sixteen-year-olds with Ewing
sarcoma did better than 17- to 24-year-olds (P¼0.021), with a
significant improvement in survival over time (P¼0.005), again
particularly marked between 1979–1984 and 1985–1989. Rhabdo-
myosarcoma (RMS) survival decreased with increasing age
(Po0.001), with no improvement over time and 5-year survival
of only 29% in the latest period. For other specified types of STS
combined, there was no significant improvement in survival over
time. For unspecified STSs, survival improved significantly
between 1979 and 1995 but not subsequently. There were no
significant trends in survival with TDI for any specified types of
bone and STS.
Table 5 shows 5-year relative survivals among patients with
GCTs by primary site. For testicular GCTs, survival increased with
advancing age at diagnosis (Po0.001). There was a consistent
improvement in 5-year survival over time (Po0.001), reaching
96% in the latest period. Ovarian GCTs showed similar patterns of
survival. For CNS GCTs, there were no significant differences in
Table 4 Five-year relative survival (%) of patients with bone and soft tissue sarcomas diagnosed at age 13–24 during 1979–2001 in England
Osteosarcoma Ewing sarcoma RMS Other specified STS Unspecified STS
N % PN % PN % PN % PN % P
Sex
Male 638 44 0.008 356 37 0.990 241 31 0.329 403 57 0.446 188 51 0.069
Female 407 53 215 39 161 38 397 61 133 58
Age (years)
13–16 480 47 0.810 247 44 0.021 172 42 o0.001 191 67 0.065 80 59 0.159
17–20 394 48 207 30 159 30 276 56 112 55
21–24 171 48 117 38 71 25 333 56 129 51
Deprivation
Most affluent 216 48 0.996 118 42 0.974 92 33 0.733 157 58 0.258 62 50 0.063
2 216 46 127 35 71 41 149 63 58 45
3 198 46 117 37 76 34 148 61 68 62
4 215 48 114 34 82 28 177 57 77 56
Most deprived 200 48 95 41 81 36 169 55 56 57
Year of diagnosis
1979–1984 311 38 o0.001 152 26 0.005 92 33 0.430 153 58 0.294 71 44 0.007
1985–1989 235 55 124 41 122 39 168 56 77 49
1990–1995 246 50 138 43 99 33 217 57 98 61
1996–2001 253 49 157 42 89 29 262 62 75 59
RMS¼rhabodomyosarcoma; STS¼soft tissue sarcoma.
Table 5 Five-year relative survival (%) of patients with GCTs diagnosed at age 13–24 during 1979–2001 in England
Testis Ovary CNS Others
N % PN % PN % PN % P
Sex
Male 3788 90 132 73 0.260 102 51 o0.001
Female 417 87 26 81 77 85
Age (years)
13–16 155 83 o0.001 142 83 0.120 63 76 0.329 21 57 0.348
17–20 1120 89 145 87 54 80 67 64
21–24 2513 92 130 90 41 66 91 68
Deprivation
Most affluent 755 89 0.267 97 82 0.716 35 77 0.413 29 45 0.246
2 775 90 72 90 37 81 35 71
3 763 92 81 86 33 69 37 65
4 742 91 84 89 22 78 36 69
Most deprived 753 91 83 85 31 68 42 72
Year of diagnosis
1979–1984 734 83 o0.001 105 72 o0.001 29 66 0.178 56 63 0.083
1985–1989 908 87 86 85 28 64 41 59
1990–1995 1010 93 109 94 57 83 44 71
1996–2001 1136 96 117 94 44 77 38 71
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sites, females had a substantially superior 5-year survival
(Po0.001). None of the subgroups showed a trend with TDI.
Table 6 shows 5-year relative survivals of patients with
carcinomas of selected sites. For head and neck carcinomas
(excluding thyroid), females had a better survival than males
(P¼0.001). There was a trend of decreasing survival with
increasing deprivation, but no trend with age. Survival steadily
improved over time (P¼0.003). Thyroid carcinoma showed a 97%
or higher survival throughout the study period, with no significant
variations in age, sex and deprivation (data not shown). For
carcinoma of lung, there was a significant improvement over time
(P¼0.046) and females had a higher survival (P¼0.052). For
carcinoma of breast, survival decreased with increasing age but the
number of cases below age 21 years was very small. There was a
borderline significant trend for improved survival over time
(P¼0.055). For ovarian carcinoma, there was a marked improve-
ment in survival between 1990–1995 and 1996–2001. This may in
part reflect changes in coding between ICD-O1 and ICD-O2 so that
additional, lower-grade ovarian tumours were included in the
1996–2001 data. No trend with age was seen. Carcinoma of cervix
showed a marked improvement between 1979–84 and 1985–89
(P¼0.012), but survival has remained at the same level since. For
colorectal carcinomas, females had a substantially better survival
than males (Po0.001). Survival increased significantly over time,
particularly in the most recent period. The most deprived group
had the lowest survival (P¼0.001). Numbers of carcinomas of
other sites were too small for separate analysis.
DISCUSSION
This study presents the first national data for England on cancer
survival among TYAs. It is now acknowledged that the special
needs of cancer patients aged 0–18 years would be best served by
principal treatment centres providing age-appropriate facilities
and managed by dedicated multidisciplinary teams (National
Collaborating Centre for Cancer, 2005). For 19- to 24-year-olds,
unhindered access to such expert teams is recommended. It has
been suggested that in this age group in the United States, low
recruitment to clinical trials contributes to the comparatively poor
improvements in cancer survival (Bleyer et al, 2007). A recent
study has compared clinical trial inclusion rates of children with
those of TYAs in Great Britain who have cancers relevant to both
age ranges and for which phase III trials are in progress
(leukaemia, lymphoma, CNS tumours, sarcoma and testicular
GCT). Results for cases diagnosed in 2005–2007 show that 56% of
total incident cases aged 5–14 years are entered into trials
compared with only 20% of 15- to 24-year-olds. Trial inclusion for
CNS tumours was particularly low (Whelan and Fern, 2008). The
baseline data on survival trends presented here are of importance
in monitoring future progress in cancer survival in TYAs and
assessing the impact of new specialist TYA cancer units, including
recruitment to clinical trials.
In this study, we have analysed survival by predefined
morphological groups of cancers, appropriate to the TYA age
range, using national data covering more than 30000 incident
cases over a 23-year period. Overall, there were marked improve-
ments in survival during the study period especially for all
subgroups of leukaemia and NHL. However, for certain other
groups, the results are less encouraging. Both osteosarcoma and
Ewing sarcoma showed a step change in survival between the two
early periods but then no further increase after 1989. There was no
improvement for RMS and other STS. Although survival among
children diagnosed with osteosarcoma up to 1997 in Britain was
only slightly better than that in TYAs reported here, children with
Ewing sarcoma and RMS showed more marked improvements and
better survivals than their TYA counterparts (Stiller et al, 2006;
Pastore et al, 2006). During 1993–1997, in children 5-year survival
was 67% for Ewing sarcoma and 65% for RMS, but in TYAs during
1996–2001, the respective survivals were 42 and 29%. For RMS,
this may partly be due to a higher proportion of TYA patients with
more aggressive histologies, but this cannot entirely explain the
poor outcomes in TYAs with bone and soft tissue sarcomas in
general.
High-grade CNS tumours in TYAs showed little or no
improvements in survival during the study period, and this was
also the case for British children up to 1997 with comparable
tumours (Peris-Bonet et al, 2006). Clearly, the clinical management
of high-grade CNS tumours in young people presents a major
Table 6 Five-year relative survival (%) of patients with selected carcinoma diagnosed at age 13–24 during 1979–2001 in England
Head and neck
a Lung Female breast Ovary Cervix Colorectal Other GU Other GI
N % PN % PN % PN % PN % PN % PN 5 years PN 5 years P
Sex
Male 305 70 0.001 80 46 0.052 268 52 o0.001 312 83 0.002 177 25 0.956
Female 271 82 66 63 458 61 572 79 886 79 281 69 206 72 166 20
Age (years)
13–16 143 74 0.375 17 64 0.433 10 70 0.041 43 78 0.425 5 60 0.293 86 60 0.090 43 67 0.003 48 28 0.055
17–20 186 72 32 56 57 75 164 84 75 87 164 60 138 73 104 27
21–24 247 80 97 51 391 58 365 76 806 78 299 62 337 82 191 19
Deprivation
Most affluent 102 82 0.034 24 57 0.109 77 57 0.985 111 72 0.258 103 82 0.703 108 66 0.001 99 81 0.299 53 24 0.842
2 111 75 23 65 104 62 101 85 142 76 100 71 93 77 61 26
3 111 78 27 63 78 65 112 78 188 78 113 59 110 82 68 20
4 122 76 35 59 104 56 117 76 206 81 98 65 104 79 82 21
Most deprived 130 69 37 32 95 62 131 83 247 78 130 48 112 74 79 24
Year of diagnosis
1979–1984 146 67 0.003 39 46 0.046 103 53 0.055 119 75 0.013 199 69 0.012 127 54 0.003 132 73 0.091 93 19 o0.001
1985–1989 120 74 28 50 113 63 119 76 219 81 111 58 124 83 83 22
1990–1995 137 78 40 50 127 62 138 73 243 84 124 58 160 78 83 19
1996–2001 173 83 39 67 115 64 196 87 225 80 187 70 102 83 84 31
aExcluding thyroid.
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rates for GCTs, with equivalent improvement in 5-year survival for
both testicular and ovarian tumours. Across all ages, nearly all
testicular tumours are of germ-cell origin, so that the high survival
rates previously reported for testicular cancer can be interpreted as
survival from GCTs of the testis. However, most ovarian cancers
are carcinomas, and survival rates for ovarian cancer (Coleman
et al, 1999) do not reflect survival from ovarian GCTs. This is
particularly important in TYAs, as GCTs are the predominant
ovarian malignancy in this age group (Birch et al, 2003).
About 80% of cancers overall are carcinomas, but these
constitute only 16% of TYA cancers (Alston et al, 2007).
Carcinomas of most sites in the present series show favourable
survival rates compared with cancers at those sites across all ages
(Coleman et al, 1999). This suggests that the TYA cases may have
histologically lower-grade tumours than older cases and/or differ
biologically. However, survival from breast carcinoma in TYAs is
similar to breast cancer in general (Coleman et al, 1999). Females
have higher survival rates for most types of cancer, and this holds
true for TYAs; possible explanations include earlier presentation in
females and less aggressive tumour biology.
Cancer survival rates among older patients in England and
Wales are strongly influenced by socioeconomic status (Coleman
et al, 1999), but only small non-significant differences were seen in
children. In this study, most cancers showed no association
between TDI and survival, but for leukaemias and carcinomas
overall, there were significant trends towards poorer survival with
increasing deprivation, particularly for colorectal and head and
neck carcinomas. These latter cancers, which show marked
associations between survival and deprivation in older patients
(Coleman et al, 1999), are aetiologically linked to lifestyle factors
also associated with deprivation, such as tobacco smoking and
poor diet (IARC, 1986; Key et al, 2004). These factors may
influence survival due to general poor health. Other considerations
include speed of seeking medical healthcare, referral patterns and
clinical management in socioeconomically deprived areas.
In conclusion, although there were marked increases in survival
over time for all cancers combined, for some diagnostic groups,
little or no improvements were seen. These results provide baseline
data against which to compare outcomes in patients treated in the
developing specialist TYA cancer units and in those entered into
clinical trials. The data serve to identify the patient groups that
present the greatest clinical challenges.
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